CASE REPORT article
Front. Oncol.
Sec. Hematologic Malignancies
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1635856
Obinutuzumab Combined with Bendamustine for the Treatment of Hairy Cell Leukemia Variant: A Case Report and Literature Review
Provisionally accepted
Junjun Bai
Yi ZhangKangqi LvBei Zhang
Wang HongxiaZhixin PeiYingxin ZhaoJingjing GuHuimin WuQinglin Song*- The People's Hospital of Jiaozuo City, Jiaozuo, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Hairy cell leukemia variant (HCL-v) is a rare and more aggressive subtype of B-cell leukemia. While it shares certain clinical features with classical hairy cell leukemia (HCL-c), HCL-v typically follows a more malignant course and responds poorly to conventional therapies. We report a case of HCL-v in a 57-year-old male who was admitted with splenomegaly and abnormal blood counts. Based on bone marrow morphology and immunophenotyping, a diagnosis of HCL-v was established.The patient was treated with a combination of obinutuzumab and bendamustine.Following treatment, his blood counts normalized, spleen size significantly reduced, and bone marrow reassessment confirmed complete remission (CR) with minimal residual disease (MRD) negativity. The patient is currently undergoing maintenance therapy with obinutuzumab and remains in good clinical condition. This case demonstrates the promising clinical efficacy of obinutuzumab combined with bendamustine in treating HCL-v, suggesting its potential as a therapeutic option.However, long-term outcomes warrant further investigation.
Keywords: hairy cell leukemia variant, Obinutuzumab, bendamustine, targeted therapy, BRAF wild-type
Received: 27 May 2025; Accepted: 25 Jul 2025.
Copyright: © 2025 Bai, Zhang, Lv, Zhang, Hongxia, Pei, Zhao, Gu, Wu and Song. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Qinglin Song, The People's Hospital of Jiaozuo City, Jiaozuo, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.